Back to announcement
20240528_SDPC_Laporan Informasi dan Fakta Material_31643523_lamp1.pdf
Other Text extracted SDPCSource file signed link, expires in 15 minutes
Extracted text 2
Page 1 OCR 0.908
MPI PT MILLENNIUM PHARMACON INTERNATIONAL Tbk No. 1 277/MPI/DIR/V/2024 Jakarta, 28 Mei 2024 Lampiran : - Perihal : Laporan Informasi atau Fakta Material Yth. Kepala Eksekutif Pengawas Pasar Modal Otoritas Jasa Keuangan Gedung Soemitro Djojohadikusumo Jalan Lapangan Banteng Timur 2-4 Jakarta 10710 Sehubungan dengan Peraturan Otoritas Jasa Keuangan (OIK) no: 31/POJK.04/2015 tanggal 16 Desember 2015 tentang Keterbukaan Informasi atas Fakta Material oleh Emiten atau Perusahaan Publik dan Surat Keputusan Direksi PT Bursa Efek Indonesia No. Kep-00066/BE1/09-2022 tanggal 30 September 2022 perihal Perubahan Peraturan Nomor I-E tentang Kewajiban Penyampaian Informasi, dengan ini kami menyampaikan Laporan Informasi atau Fakta Material sebagai berikut : In reference to Otoritas Jasa Keuangan (OJK) Regulation No.: 31/POJK.04/2015 dated 16 December 2015 regarding Disclosure Information of Material Fact by Issuer or Public Company and PT Bursa Efek Indonesia's Board of Director Decree No. Kep-00066/BEI/09-2022 dated 30 September 2022 regarding to the Changes on the Provision No. I-E regarding Obligation of Information Submision, we hereby disclose the information and Material Fact as follow: Nama Emiten atau Perusahaan Publik/Issuer: PT Millennium Pharmacon International Tbk (“Perseroan”) Bidang Usaha/Scope of Business : Distribusi produk farmasi, suplemen makanan dan alat kesehatan Telepon/Phone 1 (021) 2708 5961, (021) 2708 5964 Faksimili/Facsimile 1 (021)2708 5958 Alamat surat elektronik/e-mail 1 investor.relation@mpi-pharmaniaga.co.id 1 | Tanggal kejadian Date Event 22 Mei 2024 May 22”, 2024 2 | Jenis Informasi atau Fakta Material Type of Information or Material Facts Peningkatan Modal Dasar dan Modal ditempatkan | The increase of authorized capital and issued and dan disetor pada Entitas Anak Perseroan paid capital of the subsidiary of the Company 3 | Uraian Informasi atau Fakta Material Description of Information or Material Facts a) Pada tanggal 22 Mei 2024, PT Digital Pharma | d) On May 224, 2024, PT Digital Pharma Andalan Indonesia (“DPAI”), entitas anak Andalan Indonesia, a subsidiary of the Perseroan — telah — menandatangani — Akta Company signed the deed of increasing peningkatan modal dasar dan modal disetor authorized capital and issued and paid capital sebagai berikut : as follows: Crown Bungur-Arteri-2-4th-Ftoors KA Jl. Sultan Iskandar Muda No. 18, Jakarta 12240, Indonesia TRACE (score, ) Phone : 46221 27085961 Fax : 46221 27085958 MEMBER
Page 2 OCR 0.881
MPI PT MILLENNIUM PHARMACON INTERNATIONAL Tbk Modal Dasar Modal Authorized Capital | Issued and paid up Ditempatkan dan capital disetor Semula : Semula : Initially Initially Rp 1.000.000.000,- | Rp 250.000.000,- IDR 1.000.000.000,- | IDR 250.000.000, - Menjadi : Menjadi : Become Become Rp 5.000.000.000,- | Rp 4.100.000.000,- IDR 5.000.000.000,- | IDR 4.100.000.000,- b) Peningkatan Modal ditempatkan dan disetor DPAI tersebut sejumlah Rp 3.850.000.000,- telah disetor penuh oleh Perseroan, c) Susunan Pemegang Saham DPAI setelah b) The increase of DPAI issued and paid up capital by an amount IDR 3.850.000.000,- has been fully paid by the Company : c) The composition of shareholders of DPAI penambahan modal menjadi : subseguent to the increase is as follows: Nama Jumlah | Nilai Nominal Yo Shareholder | Number | Nominal Value 1, Pemegang | Saham Saham Name a of Shares Saham Shares PT 40.975 | 4.097.500.000,- | 99,94 PT 40.975 | 4.097.500.000,- | 99.94 Millennium Millennium Pharmacon Pharmacon International International Tbk Tbk Joefly 25 2.500.000,- | 0,06 Joefiy 25 2.500.000- | 0,06 Joesoef Joeseof Bahroeny Bahroeny Jumlah 41.000 | 4.100.000.000 | 100,00 Total Toon | aToo.cooooo: | To000 4 | Dampak kejadian, informasi atau fakta material | Impact for such information or material fact tersebut terhadap kegiatan operasional, hukum, | towards operational activity, legal, financial kondisi keuangan, atau kelangsungan usaha | condition or business continuity of Issuer or Emiten atau Perusahaan Publik Public Company Kepemilikan saham perseroan terhadap DPAI | The company's share ownership in DPAI becomes menjadi 99,94Yo 99. IA KG 5 | Keterangan lain-lain Other Information Tidak ada None Hormat kami, PT Millennium PT. MELENNUUM aymacon International Tbk INATIONAL Tok Nama: Ahmad birf Abu Bakar Jabatan: Direktur Utama Tembusan: PT Bursa Efek Indonesia up. Crown Bungur Aa —Pyirmkei — tin Direksiy Arteri 2-4th Floors Jl. Sultan Iskandar Muda No. 18, Jakarta 12240, Indonesia Phone : 46221 27085961 Fax : #6221 27085958
Names mentioned 11 people and organisations named in the text · linked when the evidence is strong
unresolved
org
PT Bursa Efek Indonesia's Board
p.1
unresolved
org
PT Digital Pharma
p.1
unresolved
org
PT Digital Pharma Andalan Indonesia
p.1
unresolved
org
PT Millennium
p.2
unresolved
org
PT. MELENNUUM
p.2
unresolved
person
Nama: Ahmad birf Abu Bakar
· Jabatan: Direktur Utama
p.2 ×2
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.